Cell therapy company Eyestem announced it has raised $6.4 million in a Series A funding round led by Biological E. Limited (BE), Alkem, NATCO and Anurag and Karan Bagaria, promoters of Kemwell Biopharma.
Existing investors Endiya Partners and Kotak Private Equity also participated in the current funding round. Post this funding, Eyestem is valued at $46.4 million, the statement said.
Commenting on the development, Jogin Desai, Founder and Chief Executive Officer of Eyestem, said: ”Post this funding, we will remain focused on solidifying our cell therapy platform and moving our flagship product for Dry AMD through early clinical trials of an international standard.”
”Eyecyte-RPE, the company’s patented flagship product, is an experimental treatment for Dry Age-Related Macular Degeneration (Dry AMD) and the company has other products in the pipeline for the treatment of incurable diseases affecting humanity,” the statement added.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.